sch442416
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00531193)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A2a receptorANTAGONIST
ADORA2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 5-amino-7-(3-(4-methoxyphenyl)propyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
- sch442416
- sch442416
- sch442416
- sch 442416
- sch-442416
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00531193 | Phase 1 | Sep 1, 2007 | Biogen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1